Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience

BACKGROUND: This retrospective study evaluates patient-reported outcomes in patients with multiple sclerosis (MS) spasticity who were treated with a cannabinoid oromucosal spray (Sativex®, USAN name: nabiximols) after not sufficiently responding to previous anti-spasticity medications. METHODS: Of 2...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Neurol
Autors principals: D’hooghe, Marie, Willekens, Barbara, Delvaux, Valerie, D’haeseleer, Miguel, Guillaume, Daniel, Laureys, Guy, Nagels, Guy, Vanderdonckt, Patrick, Van Pesch, Vincent, Popescu, Veronica
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2021
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8218396/
https://ncbi.nlm.nih.gov/pubmed/34157999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-021-02246-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars